What is the Current Clinical Impact of the CYP2CTG Haplotype?
Само за регистроване кориснике
2024
Аутори
Ingelman-Sundberg, MagnusJukić, Marin
Bråten, Line Skute
Kringen, Marianne Kristiansen
Molden, Espen
Информативни прилог (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
We read with great interest the paper by Zubiaur et al.1 on the analysis of a genotype–phenotype relationship of the CYP2C:TG haplotype. This study, including 225 patients receiving one of 6 different drugs and liver pieces from 135 children (median age 7 years), is in contrast to 2 studies by Bråten et al. using in vivo data from 875 escitalopram-treated2 and 840 sertraline-treated3 Norwegian patients, respectively, in which significantly increased rate (+20 to 25%) of CYP2C19-dependent metabolism of these drugs was found for the CYP2C:TGhaplotype.
Извор:
Clinical Pharmacology and Therapeutics, 2024, 115, 2, 183-183Издавач:
- John Wiley and Sons Inc
DOI: 10.1002/cpt.3094
ISSN: 0009-9236
PubMed: 37984075
WoS: 001107388700001
Scopus: 2-s2.0-85177230656
Институција/група
PharmacyTY - JOUR AU - Ingelman-Sundberg, Magnus AU - Jukić, Marin AU - Bråten, Line Skute AU - Kringen, Marianne Kristiansen AU - Molden, Espen PY - 2024 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5300 AB - We read with great interest the paper by Zubiaur et al.1 on the analysis of a genotype–phenotype relationship of the CYP2C:TG haplotype. This study, including 225 patients receiving one of 6 different drugs and liver pieces from 135 children (median age 7 years), is in contrast to 2 studies by Bråten et al. using in vivo data from 875 escitalopram-treated2 and 840 sertraline-treated3 Norwegian patients, respectively, in which significantly increased rate (+20 to 25%) of CYP2C19-dependent metabolism of these drugs was found for the CYP2C:TGhaplotype. PB - John Wiley and Sons Inc T2 - Clinical Pharmacology and Therapeutics T1 - What is the Current Clinical Impact of the CYP2CTG Haplotype? VL - 115 IS - 2 SP - 183 EP - 183 DO - 10.1002/cpt.3094 ER -
@article{ author = "Ingelman-Sundberg, Magnus and Jukić, Marin and Bråten, Line Skute and Kringen, Marianne Kristiansen and Molden, Espen", year = "2024", abstract = "We read with great interest the paper by Zubiaur et al.1 on the analysis of a genotype–phenotype relationship of the CYP2C:TG haplotype. This study, including 225 patients receiving one of 6 different drugs and liver pieces from 135 children (median age 7 years), is in contrast to 2 studies by Bråten et al. using in vivo data from 875 escitalopram-treated2 and 840 sertraline-treated3 Norwegian patients, respectively, in which significantly increased rate (+20 to 25%) of CYP2C19-dependent metabolism of these drugs was found for the CYP2C:TGhaplotype.", publisher = "John Wiley and Sons Inc", journal = "Clinical Pharmacology and Therapeutics", title = "What is the Current Clinical Impact of the CYP2CTG Haplotype?", volume = "115", number = "2", pages = "183-183", doi = "10.1002/cpt.3094" }
Ingelman-Sundberg, M., Jukić, M., Bråten, L. S., Kringen, M. K.,& Molden, E.. (2024). What is the Current Clinical Impact of the CYP2CTG Haplotype?. in Clinical Pharmacology and Therapeutics John Wiley and Sons Inc., 115(2), 183-183. https://doi.org/10.1002/cpt.3094
Ingelman-Sundberg M, Jukić M, Bråten LS, Kringen MK, Molden E. What is the Current Clinical Impact of the CYP2CTG Haplotype?. in Clinical Pharmacology and Therapeutics. 2024;115(2):183-183. doi:10.1002/cpt.3094 .
Ingelman-Sundberg, Magnus, Jukić, Marin, Bråten, Line Skute, Kringen, Marianne Kristiansen, Molden, Espen, "What is the Current Clinical Impact of the CYP2CTG Haplotype?" in Clinical Pharmacology and Therapeutics, 115, no. 2 (2024):183-183, https://doi.org/10.1002/cpt.3094 . .